Scandinavian Real Heart AB (Publ) (HEART.ST)
SEK 12.54
(-2.79%)
SEK 12.54
(-2.79%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -67.25 Million SEK | -32.72% |
| 2022 | -13.73 Million SEK | -36.08% |
| 2021 | -10.09 Million SEK | -20.63% |
| 2020 | -8.36 Million SEK | -22.48% |
| 2019 | -6.83 Million SEK | 19.95% |
| 2018 | -8.53 Million SEK | 13.13% |
| 2017 | -13.46 Million SEK | -164.43% |
| 2016 | -3.71 Million SEK | -152.85% |
| 2015 | -1.46 Million SEK | 10.07% |
| 2014 | -1.63 Million SEK | -665.31% |
| 2013 | -213.48 Thousand SEK | -1045.23% |
| 2012 | 22.58 Thousand SEK | 155.86% |
| 2011 | -40.43 Thousand SEK | 46.16% |
| 2010 | -75.08 Thousand SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -5.71 Million SEK | -96.3% |
| 2024 Q1 | -2.53 Million SEK | 94.55% |
| 2023 FY | - SEK | -32.72% |
| 2023 Q2 | -2.77 Million SEK | 31.34% |
| 2023 Q1 | -4.03 Million SEK | -180.88% |
| 2023 Q3 | -7.78 Million SEK | -180.68% |
| 2023 Q4 | -52.65 Million SEK | -576.53% |
| 2022 Q1 | -2.62 Million SEK | 47.47% |
| 2022 FY | - SEK | -36.08% |
| 2022 Q4 | 4.99 Million SEK | 56.44% |
| 2022 Q3 | 3.19 Million SEK | 201.22% |
| 2022 Q2 | -3.15 Million SEK | -20.18% |
| 2021 Q2 | -2.11 Million SEK | -26.94% |
| 2021 FY | - SEK | -20.63% |
| 2021 Q1 | -1.66 Million SEK | 19.32% |
| 2021 Q4 | -4.99 Million SEK | -281.08% |
| 2021 Q3 | -1.31 Million SEK | 38.15% |
| 2020 Q2 | -1.68 Million SEK | 24.06% |
| 2020 Q1 | -2.22 Million SEK | -130.19% |
| 2020 Q3 | -2.38 Million SEK | -41.42% |
| 2020 Q4 | -2.06 Million SEK | 13.31% |
| 2020 FY | - SEK | -22.48% |
| 2019 Q2 | -2.23 Million SEK | -46.8% |
| 2019 Q4 | 7.36 Million SEK | 721.4% |
| 2019 Q3 | -1.18 Million SEK | 46.95% |
| 2019 FY | - SEK | 19.95% |
| 2019 Q1 | -1.52 Million SEK | 60.17% |
| 2018 FY | - SEK | 13.13% |
| 2018 Q4 | -3.81 Million SEK | -114.34% |
| 2018 Q3 | -1.78 Million SEK | -39.98% |
| 2018 Q2 | -1.27 Million SEK | 19.42% |
| 2018 Q1 | -1.57 Million SEK | 77.3% |
| 2017 Q3 | -1.44 Million SEK | -56.8% |
| 2017 FY | - SEK | -164.43% |
| 2017 Q1 | -533.07 Thousand SEK | 38.25% |
| 2017 Q2 | -920.93 Thousand SEK | -72.76% |
| 2017 Q4 | -6.95 Million SEK | -381.8% |
| 2016 Q1 | -804.08 Thousand SEK | -41.87% |
| 2016 FY | - SEK | -152.85% |
| 2016 Q4 | -863.23 Thousand SEK | -15.2% |
| 2016 Q3 | -749.35 Thousand SEK | 48.2% |
| 2016 Q2 | -1.44 Million SEK | -79.91% |
| 2015 Q1 | -445.78 Thousand SEK | 55.24% |
| 2015 FY | - SEK | 10.07% |
| 2015 Q4 | -566.76 Thousand SEK | -158.5% |
| 2015 Q3 | -219.25 Thousand SEK | 7.68% |
| 2015 Q2 | -237.49 Thousand SEK | 46.72% |
| 2014 FY | - SEK | -665.31% |
| 2014 Q3 | -339.72 Thousand SEK | -175.99% |
| 2014 Q2 | -123.09 Thousand SEK | 29.63% |
| 2014 Q4 | -996.03 Thousand SEK | -193.19% |
| 2014 Q1 | -174.92 Thousand SEK | 0.0% |
| 2013 FY | - SEK | -1045.23% |
| 2012 FY | - SEK | 155.86% |
| 2011 FY | - SEK | 46.16% |
| 2010 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Acarix AB (publ) | -77.12 Million SEK | 12.8% |
| ADDvise Group AB (publ) | 411.9 Million SEK | 116.327% |
| ADDvise Group AB (publ) | 411.9 Million SEK | 116.327% |
| Arcoma AB | 6.24 Million SEK | 1176.345% |
| Bactiguard Holding AB (publ) | -89.98 Million SEK | 25.263% |
| BICO Group AB (publ) | 322.3 Million SEK | 120.866% |
| Boule Diagnostics AB (publ) | 65.97 Million SEK | 201.926% |
| CellaVision AB (publ) | 207.24 Million SEK | 132.45% |
| Clinical Laserthermia Systems AB (publ) | -68.4 Million SEK | 1.69% |
| Chordate Medical Holding AB (publ) | -27.94 Million SEK | -140.669% |
| C-Rad AB (publ) | 48.9 Million SEK | 237.514% |
| Duearity AB (publ) | -24.77 Million SEK | -171.399% |
| Dignitana AB (publ) | -264 Thousand SEK | -25373.508% |
| Episurf Medical AB (publ) | -87.7 Million SEK | 23.318% |
| Getinge AB (publ) | 5.92 Billion SEK | 101.134% |
| Iconovo AB (publ) | -35.33 Million SEK | -90.319% |
| Integrum AB (publ) | 8.76 Million SEK | 867.561% |
| Luxbright AB (publ) | -23.86 Million SEK | -181.773% |
| Mentice AB (publ) | 28.87 Million SEK | 332.917% |
| OssDsign AB (publ) | -122.02 Million SEK | 44.886% |
| Paxman AB (publ) | 31.22 Million SEK | 315.345% |
| Promimic AB (publ) | -3.68 Million SEK | -1725.464% |
| Qlife Holding AB (publ) | -150.5 Million SEK | 55.317% |
| SciBase Holding AB (publ) | -51.82 Million SEK | -29.754% |
| ScandiDos AB (publ) | -13.35 Million SEK | -403.519% |
| Sectra AB (publ) | 615.06 Million SEK | 110.934% |
| Sedana Medical AB (publ) | -51.67 Million SEK | -30.143% |
| Senzime AB (publ) | -118.82 Million SEK | 43.403% |
| SpectraCure AB (publ) | -20.96 Million SEK | -220.712% |
| Stille AB | 56.04 Million SEK | 220.002% |
| Vitrolife AB (publ) | -3.18 Billion SEK | 97.889% |
| Xvivo Perfusion AB (publ) | 126.57 Million SEK | 153.131% |